Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23214404 | 0.83 | FBP1 (0.50) | FBP1KDM4EAHRCYP1A2LMNA | |
| SCHEMBL6802200 | 0.81 | FBP1 (0.51) | FBP1KDM4ELMNAALDH1A1HPGD | |
| SCHEMBL3274432 | 0.81 | MAPT (0.47) | FBP1KDM4EAHRCYP1A2LMNA | |
| SCHEMBL3822181 | 0.79 | FBP1 (0.41) | FBP1KDM4EAHRCYP1A2LMNA | |
| SCHEMBL3822179 | 0.79 | FBP1 (0.41) | FBP1KDM4EAHRCYP1A2LMNA | |
| SCHEMBL21179348 | 0.79 | FBP1 (0.47) | FBP1KDM4EAHRCYP1A2LMNA | |
| SCHEMBL2145291 | 0.79 | KDM4E (0.51) | FBP1KDM4EAHRCYP1A2LMNA | |
| SCHEMBL9750715 | 0.79 | CYP1A2 (0.41) | FBP1KDM4EAHRCYP1A2LMNA | |
| SCHEMBL11164366 | 0.79 | TARBP2 (0.42) | FBP1KDM4EAHRCYP1A2LMNA | |
| SCHEMBL779128 | 0.79 | TARBP2 (0.42) | FBP1KDM4EAHRCYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250262201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | AGIOS PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2023164234-A9 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| WO-2010013222-A1 | PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-02-04 | — | — | WO | disclosed |
| US-7645778-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2044038-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Cornerstone Therapeutics Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2006078621-A9 | 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| WO-2007146066-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CRITICAL THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146066-A2 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CRITICAL THERAPEUTICS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | FBP1 3231/4885KDM4E 104/4885AHR 599/4885 |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | P2RY1, P2RY11, P2RY2 | FBP1 486/4885KDM4E 4419/4885AHR 610/4885 |
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | PAH, KDM8, PHF8 | FBP1 3231/4885KDM4E 104/4885AHR 599/4885 |
| US-20250171437-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | PAH, BCKDK, PKM | FBP1 3929/4885KDM4E 50/4885AHR 426/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | FBP1 3231/4885KDM4E 104/4885AHR 599/4885 |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | FBP1 3231/4885KDM4E 104/4885AHR 599/4885 |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | FBP1 3231/4885KDM4E 104/4885AHR 599/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | FBP1 4104/4885KDM4E 3410/4885AHR 1358/4885 |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | FBP1 3231/4885KDM4E 104/4885AHR 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.